What’s next for 23andMe? | PharmaVoice
Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.| PharmaVoice
Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.| PharmaVoice
Multi-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes| www.gsk.com
The sobering fact about drug development is that it takes too long and costs too much money. 23andMe wants to change all that. At the annual meeting of the American Society of Human Genetics this month, 23andMe computational biologist Fah Sathirapongsasuti offered some insight into how this is being done. “It’s a well-appreciated fact among […]| 23andMe Blog
By Julia Rock-Torcivia | June 20, 2025| Drug Discovery and Development
